CONCISE REPORT

Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling


ABSTRACT

Objectives: Canonical Wnt signalling has recently emerged as a key mediator of fibroblast activation and tissue fibrosis in systemic sclerosis. Here, we investigated tankyrases as novel molecular targets for inhibition of canonical Wnt signalling in fibrotic diseases.

Methods: The antifibrotic effects of the tankyrase inhibitor XAV-939 or of siRNA-mediated knockdown of tankyrases were evaluated in the mouse models of bleomycin-induced dermal fibrosis and in experimental fibrosis induced by adenoviral overexpression of a constitutively active TGF-β receptor I (Ad-TBRI).

Results: Inactivation of tankyrases prevented the activation of canonical Wnt signalling in experimental fibrosis and reduced the nuclear accumulation of β-catenin and the mRNA levels of the target gene c-myc. Treatment with XAV-939 or siRNA-mediated knockdown of tankyrases in the skin effectively reduced bleomycin-induced dermal thickening, differentiation of resting fibroblasts into myofibroblasts and accumulation of collagen. Potent antifibrotic effects were also observed in Ad-TBRI driven skin fibrosis. Inhibition of tankyrases was not limited by local or systemic toxicity.

Conclusions: Inactivation of tankyrases effectively abrogated the activation of canonical Wnt signalling and demonstrated potent antifibrotic effects in well-tolerated doses. Thus, tankyrases might be candidates for targeted therapies in fibrotic diseases.

INTRODUCTION

Canonical Wnt signalling belongs to the so-called morphogen pathways that are essential for development, but also tissue homeostasis.1 2 The central regulatory mechanism of canonical Wnt signalling is the proteolysis of β-catenin. In the absence of Wnt signals, cytosolic β-catenin is constitutively phosphorylated by the β-catenin destruction complex and targeted for proteasomal degradation. However, in the presence of Wnt proteins, the β-catenin destruction complex is inhibited, β-catenin is stabilised and translocates into the nucleus to initiate the transcription process of Wnt target genes.2

Aberrant activity of canonical Wnt signalling has been implicated in a variety of diseases3 4 and has recently emerged as a key pathway in systemic sclerosis (SSc).5 6 In SSc, the canonical Wnt pathway is activated as a result of a profound dysbalance between stimulatory and inhibitory mediators. While the ligands Wnt-1 and Wnt-10b are overexpressed, antagonists such as dickkopf-1, dickkopf -2 and Wnt-inhibitory factor are downregulated, in part in a TGF-β dependent manner.6 7 8 9 Activation of canonical Wnt signalling stimulates resting fibroblasts to differentiate into myofibroblasts and release abundant amounts of extracellular matrix. Persistently activated canonical Wnt signalling induces overexpression of either a stabilised mutant of β-catenin or Wnt-10b results in massive skin fibrosis.2 5 6 9 10 Together, these findings indicate that canonical Wnt signalling may be an interesting target for antifibrotic therapies.

Targeted inhibition of canonical Wnt signalling has long been complicated by the lack of pathway components that are amenable to pharmacological inhibition.11 Only recently, tankyrases 1 and 2 (TNKS-1 and TNKS-2) were identified as promising targets.12 TNKS-1 and TNKS-2 stimulate the proteasomal degradation of axin, thereby inhibiting the degradation of β-catenin. Thus, pharmacologic inhibition of both tankyrases by XAV-939 (3,5,7,8-tetrahydro-2-[4-(trifluoromethyl)phenyl]-4H-thiopyrano[4,3-d]pyrimidin-4-one) stabilised the β-catenin destruction complex, decreased the levels of β-catenin and selectively and efficiently inhibited canonical Wnt signalling.12

Considering the strong pro-fibrotic effects of canonical Wnt signalling, the availability of XAV-939 as a potent and selective inhibitor and the clinical need for antifibrotic therapies, we investigated inhibition of tankyrases as a novel targeted therapy for the treatment of fibrosis in preclinical models of scleroderm.

MATERIAL AND METHODS

Experimental models of dermal fibrosis

Bleomycin-induced dermal fibrosis was modelled as described.13 14 In a second model, fibrosis was induced by intradermal injections of replication-deficient type 5 adenoviruses encoding for a constitutively active TGF-β receptor type I mutant (Ad-TBRI). Injections of viruses encoding for LacZ (Ad-LacZ) served as controls.10 15

Pharmacological inhibition of tankyrases

XAV-939, a selective inhibitor of TNKS-1 and TNKS-2 (R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany), was injected in doses of 2.5 mg/kg intraperitoneal four times a day (injection volume 100 µl). Control mice were sham
Inactivated tankyrases prevents bleomycin-induced dermal fibrosis

Pharmacological inhibition of tankyrases by XAV-939 was well tolerated. No changes in the texture of the fur, activity or behaviour were observed in mice treated with XAV-939 compared with sham-treated controls during daily monitoring. We also did not observe signs of gastrointestinal toxicity such as weight loss or diarrhea.

Inhibition of tankyrases exerted potent antifibrotic effects. Treatment of bleomycin challenged mice with XAV-939 reduced dermal thickening by 50% compared with sham-treated, bleomycin challenged mice (p=0.0007) (median: 1.75 (IQR 1.60–2.00) for bleomycin and sham treatment versus median: 1.30 (IQR 1.10–1.41) for bleomycin + XAV-939) (figure 2A). The number of myofibroblasts and the hydroxyproline content were also significantly decreased in mice treated with XAV-939 (figure 2B, C).

To exclude that the antifibrotic effects of XAV-939 are due to off-target effects, we targeted the expression of tankyrases in fibrotic skin by local injections of siRNAs against TNKS-1 and TNKS-2. siRNAs efficiently reduced the mRNA levels of TNKS-1 and TNKS-2 with minimal decreases of 64±10% at the end of the injection period (p=0.04). siRNA-mediated knockdown of tankyrases reduced bleomycin-induced dermal thickening by 77±5% compared with mice injected with non-targeting siRNA (p=0.009) (figure 2D). Consistently, myofibroblast counts and the hydroxyproline content were also decreased by siRNAs treatment (figure 2E, F).

Inhibition of tankyrases prevents Ad-TBRI-induced dermal fibrosis

We have shown recently that TGF-β signalling activates canonical Wnt signalling and that canonical Wnt signalling is a downstream mediator of the profibrotic effects of TGF-β signalling. Therefore, we examined whether inhibition of tankyrases prevents Ad-TBRI-induced fibrosis. Treatment with XAV-939 inhibited dermal thickening in Ad-TBRI-treated mice with reductions of 60% compared with sham-treated, Ad-TBRI mice (median: 1.99 (IQR 1.73–2.17) for sham-treated Ad-TBRI mice versus median: 1.45 (IQR 1.26–1.61) for XAV-939 treated Ad-TBRI mice) (p=0.0009) (figure 3A). Myofibroblast counts and the hydroxyproline content were also significantly reduced by treatment with XAV-939 (figure 3B, C).

RESULTS

Inactivation of tankyrases inhibits Wnt signalling in experimental dermal fibrosis

Challenge with bleomycin as well as Ad-TBRI induced nuclear accumulation of β-catenin in dermal fibroblasts and upregulated the mRNA levels of the Wnt target gene c-myc as compared with non-fibroblast control mice (figure 1A, B). Pharmacological inhibition of tankyrases by XAV-939 completely abrogated the nuclear accumulation of β-catenin in fibroblasts (figure 1A) and also normalised the levels of c-myc in fibrotic skin (figure 1B). Similar results were obtained by siRNA-mediated knockdown (data not shown), demonstrating that targeting of tankyrases inhibits activation of canonical Wnt signalling in experimental fibrosis.
Inactivation of tankyrases reduces Wnt signalling in experimental dermal fibrosis. (A) Treatment with the tankyrase inhibitor XAV-939 inhibited the nuclear accumulation of β-catenin in fibroblast-specific protein-1 positive cells in bleomycin- and active TGF-β receptor I (Ad-TBRI)-induced skin fibrosis. (B) Inhibition of tankyrases normalises the mRNA levels of c-myc in mice challenged with bleomycin or Ad-TBRI. n=5 For each group. Access the article online to view this figure in colour.
Figure 2  Inactivation of tankyrases prevents bleomycin-induced dermal fibrosis. (A–C) Treatment with XAV-939 reduces dermal thickening (A), myofibroblast differentiation (B) and hydroxyproline content (C) in mice challenged with bleomycin. Representative trichrome-stained tissue sections are shown at 100-fold magnification. n=10 For NaCl and bleomycin, n=8 for XAV-939. (D–F) siRNA-mediated knockdown of tankyrases 1 and 2 (TNKS-1 and TNKS-2) prevented bleomycin-induced dermal thickening (D), differentiation of resting fibroblasts into myofibroblasts (E) and reduced the hydroxyproline content (F). Representative sections are shown at 100-fold magnification. n=5 For each group. Access the article online to view this figure in colour.
when inhibiting canonical Wnt signalling.\textsuperscript{11, 20} In particular, effects of XAV-939 were on target.\textsuperscript{a} are needed to investigate the anti-regression of\textsuperscript{b} tors in other organs and on vascular manifestations, to analyse\textsuperscript{c} targeted therapies in mice.\textsuperscript{d} ankyrases may thus be an interesting novel candidate for\textsuperscript{e} stages of scleroderma and (iii) is not limited by toxicity in\textsuperscript{f} mice.\textsuperscript{g} Figure 3\textsuperscript{h} \textbf{A} \textbf{B} \textbf{C} Inhibitory of tankyrase prevents active TGF-β receptor I (Ad-TBRI)-induced fibrosis. Treatment with XAV-939 prevents dermal thickening (A), myofibroblast differentiation (B) and hydroxyproline content (C) in mice infected with Ad-TBRI. Representative trichrome-stained tissue sections are shown at 100-fold magnification. n=5 For each group. Access the article online to view this figure in colour.

ACKNOWLEDGEMENTS We thank Anna-Maria Herrmann, Madeleine Demleitner, Verena Wäsch and Stefan Fritz for excellent technical assistance.

Competing interests PD Dr O Distler had consultancy relationship and/or has received research funding from Actelion, Bayer, Pfizer, Ergonex, BMS, Sanofi-Aventis, Sinoxa, United BioSource Corporation, medac, Biovitrum, Boehringer Ingelheim Pharma, Novartis, 4D Science and Active Biotec in the area of potential treatments of scleroderma and its complications. JHW Distler has consultancy relationships and/or has received research funding from Actelion, Pfizer, Ergonex, BMS, Celgene, Bayer Pharma, Boehringer Ingelheim, J&J Therapeutics, Sanofi-Aventis, Novartis, Amy Biopharma and Active Biotec in the area of potential treatments of scleroderma and is stock owner of 4D Science GmbH.

Patient consent Obtained.

Ethics approval This study was conducted with the approval of the ethical committees of the University of Erlangen-Nuremberg, Germany.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Additional information is available from the corresponding author upon request.

REFERENCES


Basic and translational research


Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling


Ann Rheum Dis 2013 72: 1575-1580 originally published online November 12, 2012
doi: 10.1136/annrheumdis-2012-202275

Updated information and services can be found at:
http://ard.bmj.com/content/72/9/1575

These include:

References
This article cites 20 articles, 9 of which you can access for free at:
http://ard.bmj.com/content/72/9/1575#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Connective tissue disease (4234)
Genetics (964)
Occupational and environmental medicine (29)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/